Genzyme profit shoots up; Tobira touts Phase I results;

> After failing to meet Wall Street's Q2 expectations, Celera has announced that it will cut 80 jobs--13 percent of its workforce. Celera release

> Lower R&D expenses helped Genzyme more than double its profits for the last quarter. Report

> Tobira Therapeutics says two Phase I pharmacokinetic studies for the HIV drug TAK-652 suggest the therapy is rapidly absorbed and demonstrate relatively good oral bioavailability supporting once-daily dosing. Release

> Roche missed forecasts with a 29 percent drop in first-half net profit, hit by costs related to its $47 billion acquisition of Genentech, but the company raised its full-year earnings guidance. Report

> Chelsea Therapeutics International plans to raise approximately $12.6 million in a registered direct offering. Chelsea Therapeutics release

> The FDA has delayed its review of Takeda Pharmaceutical's fixed-dose diabetes drug combing alogliptin and Actos to September 4. Report

> Despite beating expectations in the second quarter, biopharma industry tracker IMS Health said it will restructure and cut 850 jobs. Report

> Contract research organization Xcelience is moving forward with plans to expand its workforce will move in both formulation development and quality assurance. Xcelience release

Pharma News

> In an aim to encourage innovation, the National Institute for Health and Clinical Excellence could incentivize the pharma industry, offering higher prices for new, cutting-edge treatments. That's the suggestion from Sir Ian Kennedy, who has been studying NICE's effects on innovation at the agency's request. Report

> Big Pharma's $80 billion cost-cutting deal with Washington isn't as comprehensive as the industry had hoped. In last night's news conference, President Obama suggested, "We might be able to get $100 billion out of them, or more." And that's just the beginning. Report

> Eli Lilly is close to settling another slate of Zyprexa marketing cases. According to the company's quarterly report, it's in "advanced discussions" with attorneys general investigating the company for off-label promotions of the antipsychotic drug. Report

Vaccine News

> GlaxoSmithKline says that it expects to reap up to $2.1 billion next year from the sale of a new H1N1 vaccine. And it's already tripling its capacity to supply the antiviral Relenza as it dickers with about 50 countries over their plans to buy stockpiles of meds to fight the flu. Report

> A new study demonstrated that GlaxoSmithKline's Typherix vaccine was effective at preventing typhoid in children as young as two and that widespread vaccination campaigns targeting threatened neighborhoods can help protect an entire community. Report

> The first human trial of an H1N1 vaccine began Wednesday. Melbourne, Australia-based developer CSL has launched a human trial of its experimental H1N1 vaccine in partnership with the clinical research organization CMAX and the Royal Adelaide Hospital in South Australia. Report

And Finally... The majority of people in the United States don't get the vaccinations they need and in many cases haven't got a clue what they're missing out on, according to a pair of new surveys that highlight the shortcomings of the country's healthcare system. Report

Suggested Articles

In a pandemic world, the biotech funding environment couldn’t look brighter, and today Pfizer shone its own light.

Gilead is tapping long-term Stanford University researcher Mark Genovese, M.D., to lead its NASH, fibrosis and arthritis pipeline programs.

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…